

FORM PTO-154 (5-95 Modified)

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE

REV 11-2000

JC07 Rec'd PCT/PCTO 24 APR 2001

ATTORNEY'S DOCKET NUMBER

37921-151292

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

Not Yet Assigned

09/830319

APR 24 2001  
TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.  
PCT/AU99/00931INTERNATIONAL FILING DATE  
October 27, 1999PRIORITY DATE CLAIMED  
October 27, 1998

## TITLE OF INVENTION

**A Method Of Treatment**

## APPLICANT(S) FOR DO/EO/US

Perry F. Bartlett, Lynne Hartley, Mark Pilizzotto, Trevor Kilpatrick, Frank Kontgen, Jason Coonan, Ursula Greferath, Andrew W. Boyd, Mirella Dottori, Mary Galea, George Paxinos and Mark Murphy


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4.  The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.  A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a.  is attached hereto (required only if not communicated by the International Bureau).
  - b.  has been communicated by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a.  is attached hereto.
  - b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a.  are attached hereto (required only if not communicated by the International Bureau).
  - b.  have been communicated by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.  An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.  A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.  A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.  A **FIRST** preliminary amendment.
16.  A **SECOND** or **SUBSEQUENT** preliminary amendment.
17.  A substitute specification.
18.  A change of power of attorney and/or address letter.
19.  A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20.  A second copy of the published international application under 35 U.S.C. 154(d)(4).
21.  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22.  Certificate of Mailing by Express Mail
23.  Other items or information:

Express Mail Label No. EL 740327257 US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR Not Yet Assigned <b>09/830319</b>	INTERNATIONAL APPLICATION NO. <b>PCT/AU99/00931</b>	ATTORNEY'S DOCKET NUMBER <b>37921-151292</b>
24. The following fees are submitted:		<b>CALCULATIONS PTO USE ONLY</b>
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b>		
<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1000.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>		
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>\$1,000.00</b>
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).		<input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 <b>\$130.00</b>
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	41 - 20 =	21    x \$18.00 <b>\$378.00</b>
Independent claims	6 - 3 =	3    x \$80.00 <b>\$240.00</b>
Multiple Dependent Claims (check if applicable)		<input checked="" type="checkbox"/> <b>\$270.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$2,018.00</b>
<input checked="" type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.		<b>\$1,009.00</b>
<b>SUBTOTAL =</b>		<b>\$1,009.00</b>
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30    + <b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>		<b>\$1,009.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).		<input type="checkbox"/> <b>\$0.00</b>
<b>TOTAL FEES ENCLOSED =</b>		<b>\$1,009.00</b>
		<b>Amount to be: refunded</b> <b>\$</b>
		<b>charged</b> <b>\$</b>
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,009.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-0573</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO:		
Daniel A. Monaco Drinker, Biddle & Reath, LLP One Logan Square 18th and Cherry Streets Philadelphia, PA 19103-6996 (215) 988-3312 (215) 988-2757		
 <b>23973</b> <small>PATENT TRADEMARK OFFICE</small>		
 SIGNATURE <b>DANIEL A. MONACO</b> NAME <b>30,480</b> REGISTRATION NUMBER <b>April 24, 2001</b> DATE		

09/830319  
JC03 Rec'd CCT/PTO 24 APR 2001

PATENT

Attorney Docket No.: 37921-151292

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :  
Perry F. Barlett, et al. :  
  
Serial No.: Not Yet Assigned : Group Art Unit:  
(International Serial No. PCT/AU99/00931) : Not Yet Assigned  
  
Filed: Concurrently Herewith : Examiner:  
(International Filing Date: October 27, 1999) :  
  
For: A Method Of Treatment : Not Yet Assigned  
: :  
:

PRELIMINARY AMENDMENT


Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Kindly amend the above-identified patent application, without prejudice, as follows.

**In the Claims:**

Please cancel Claim 21, without prejudice.

<p style="text-align: center;"><b>CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10</b></p> <p>EXPRESS MAIL Mailing Label Number: EL 740327257 Date of Deposit: April 24, 2001</p> <p>I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 CFR 1.10, on the date indicated above, and addressed to: Commissioner for Patents, Washington, D.C. 20231.</p> <p> Signature of person mailing page:</p> <p>Therese McKinley Type or print name of person</p>
---

Please amend Claim 17 as follows. A mark-up of the amended claim as required by 37 C.F.R. 1.211(c)(ii) is attached hereto as Appendix A.


17. (Amended) A genetically modified animal according to claim 14 or 15 wherein the animal is a murine species.

#### **REMARKS**

Claims 1-20 are pending in the application. The claims have been amended to reduce dependencies.

Respectfully submitted,

PERRY F. BARLETT, et al.

BY: 

DANIEL A. MONACO  
Drinker, Biddle & Reath, LLP.  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
(215) 988-3312  
(215) 988-2757 – Fax  
Attorney for the Applicants

A METHOD OF TREATMENT

The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury.

5 The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.

Bibliographic details of the publications numerically referred to in this specification are

10 collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

Recent studies show that axons are guided to their targets by a system of guidance molecules

15 including Eph receptors and their ligands (1-3). The role of these molecules has been intensely studied in development of the visual system (4-6), where the reciprocal gradient expression of the Eph receptors in the retina and of their ligands in the optic tectum is the suggested basis for the formation of the retinotectal topographic map. Other observations pertinent to the role of these molecules in the developing nervous system include axonal fasciculation and establishing

20 brain commissures (7-9).

The Eph family of receptors can be divided into two groups, EphA and EphB, based on the sequence similarities of their extracellular domain (10). Each EphA receptor is able to bind several Ephrin A ligands which are associated with the membrane via a GPI-linkage, these

25 receptors show little or no binding to the transmembrane Ephrin B ligands (11, 12). The EphB group of receptors show the reverse pattern, binding predominantly to Ephrin B ligands. An exception to this 'rule' is the EphA4 (previously known as Sek1) receptor which was found to significantly bind to some of the transmembrane ligands in addition to all the GPI-linked ligands (11-13).

- 2 -

developing forebrain, hindbrain and mesoderm (14, 15). In the final stages of embryogenesis, expression of EphA4 is predominantly found within regions of the central nervous system, including the cerebral cortex, striatum, thalamus, hippocampus, and ventral spinal cord. In the hindbrain, EphA4 shows restricted expression to rhombomeres 3 and 5 (14) which suggested 5 a role of this receptor in establishing boundaries during embryogenesis. This notion was supported by over expression of dominant negative, truncated EphA4 receptor in zebrafish embryos. The resultant mutant embryos were found to have disruption in the rhombomere boundaries and an expansion of the developing retina into the diencephalon (16, 17).

10 In work leading up to the present invention, the inventors generated laboratory animals deficient in the EphA4 receptor. The EphA4 mutant animals displayed a gross motor abnormality in the hindlimbs. Anatomical analyses and anterograde tracing of cortical neurons demonstrated a severe disruption of the corticospinal tract (CST) in these animals. The CST is the single longest axonal projection in the mammalian central nervous system (18). CST neurons arise  
15 from layer V in the neocortex and extend their axons through the forebrain, midbrain and hindbrain, and terminate at various levels of the spinal cord. In primates the CST axons predominantly synapse directly with the spinal motor neurons, whereas in the rodent most of the cortical axons synapse with interneurons which then connect to the spinal motor neurons. The EphA4 null mutant animals showed specific defects in the CST both at the level of the  
20 medulla and the spinal cord, which indicates that EphA4 is required for the correct formation of the CST.

Accordingly, one aspect of the present invention contemplates a method of facilitating regeneration, growth and/or development of a central nervous system and in particular the  
25 central nervous system in a human or non-human animal said method comprising increasing, elevating or otherwise enhancing the levels of a Eph receptor or its functional equivalent.

Another aspect of the present invention provides a method of regulating axon guidance in a human or non-human animal said method comprising increasing, elevating or otherwise  
30 enhancing the levels of an Eph receptor or its functional equivalent in said human or non-human animal.

- 3 -

Still another aspect of the present invention is directed to a method for facilitating the repair or replacement of axons in a human or non-human animal, said method comprising increasing, elevating or otherwise enhancing the levels of an Eph receptor or its functional equivalent in a region surrounding the cortex and/or inhibiting, reducing or otherwise down-regulating expression of the Eph receptor or its functional equivalent when expressed in tissues outside said region surrounding the cortex and which expression leads to blockage of axonal growth.

Yet another aspect of the present invention provides for a method of inducing, promoting or otherwise facilitating repair of nervous tissue in a human or non-human animal, said method comprising increasing, elevating or otherwise enhancing the levels of an Eph receptor or its functional equivalent in a region surrounding the cortex and/or inhibiting, reducing or otherwise down-regulating expression of the Eph receptor or its functional equivalent when expressed in tissues outside said region surrounding the cortex and which expression leads to blockage of axonal growth.

The repair of nervous tissue according to this aspect of the present invention may be required following or during disease or trauma. Particular diseases contemplated by the present invention include but are not limited to brain and spinal cord injury, diseases of the upper motor neuron and diseases of the central nervous system such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.

The present invention may also be practiced by modulating levels of the ligands for Eph receptors or their functional equivalents, e.g. the ephrins or their functional equivalents.

25

Particularly preferred ephrins include ephrin-B1, ephrin-B2 and ephrin-B3. The most preferred ephrin is ephrin-B3.

The method of the present invention may be accomplished in any number of ways including 30 but not limited to administering soluble or near soluble forms of the Eph receptors or parts

thereof (e.g. fragment comprising all or part of the extracellular domain) or their functional equivalents in monomeric, dimeric or other multimeric form. Administration may be in any convenient means such as directly into the spinal cord or brain. Since it is proposed, in accordance with the present invention, that the Eph receptors or their functional equivalents regulate axon guidance in the corticospinal tract (CST), the administration of a monomeric or multimeric form of the Eph receptors or parts thereof or ligands or their functional equivalents may assist in defining pathways for axon movement.

Where Eph receptors or their functional equivalents are expressed in inappropriate tissues, 10 i.e. not in the region surrounding the CST, then soluble forms of epherins or other Eph antagonists may be administered, such as to the brain and/or spinal cord, to block the expression or function of the Eph receptors or their functional equivalents. An example of other Eph antagonists include receptor monomers or other derivatives or their functional equivalents. Labelled Eph monomers such as FLAG-tagged Eph monomers (40, 41) are 15 particularly useful antagonists.

Reference herein to "Eph receptor" means the murine Eph receptor or a functional equivalent thereof such as a human or non-murine homologue. The present invention further extends to the manipulation of derivatives of the Eph receptor or its functional equivalent. A derivative includes a part, fragment or portion of the receptor such as a single or multiple amino acid substitution, deletion and/or addition to the amino acid sequence defining the Eph receptor or its functional equivalent. The present invention further extends to ligand binding portions of the Eph receptor such as an extracellular portion of the receptor. An example of a fragment of an Eph receptor having ligand binding capacity is US Patent Application No. 25 09/104,340 entitled "Receptor ligand system and assay".

Derivatives also include single or multiple amino acid substitutions, deletions and/or additions to an Eph receptor or its functional equivalent or single or multiple nucleotide substitutions, deletions and/or additions to the genetic sequence encoding an Eph receptor or its functional 30 equivalent. "Additions" to amino acid sequences or nucleotide sequences include fusions with

- 5 -

other peptides, polypeptides or proteins or fusions to nucleotide sequences. Reference herein to an Eph receptor includes reference to all derivatives thereof including functional and non-functional derivatives as well as homologues and analogues thereof.

- 5 Analogues of an Eph receptor contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.
- 10 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH<sub>4</sub>; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylolation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with 15 succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH<sub>4</sub>.

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

20

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

30

- 6 -

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetrinitromethane to form a 3-nitrotyrosine derivative.

5

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis  
10 include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 1.

15

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having  $(CH_2)_n$  spacer groups with  $n=1$  to  $n=6$ , glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and  
20 another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of  $C_\alpha$  and  $N$ -methylamino acids, introduction of double bonds between  $C_\alpha$  and  $C_\beta$  atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini,  
25 between two side chains or between a side chain and the N or C terminus.

The present invention further contemplates chemical analogues of an Eph receptor capable of acting as antagonists or agonists of an Eph receptor or which can act as functional analogues of an Eph receptor. Chemical analogues may not necessarily be derived from an Eph receptor  
30 but may share certain conformational similarities. Alternatively, chemical analogues may be

- 7 -

specifically designed to mimic certain physiochemical properties of an Eph receptor. Chemical analogues may be chemically synthesised or may be detected following, for example, natural product screening.

- 5 These types of modifications may be important to stabilise an Eph receptor if administered to an individual or for use as a diagnostic reagent.

Other derivatives contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule.

- 10 Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.

- 8 -

TABLE 1

Non-conventional amino acid	Code	Non-conventional amino acid	Code
5 $\alpha$ -aminobutyric acid	Abu	L-N-methylalanine	Nmala
$\alpha$ -amino- $\alpha$ -methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
aminocyclopropane- carboxylate	Cpro	L-N-methyleasparagine	Nmasn
10 aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbornyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
cyclohexylalanine		L-N-methylglutamic acid	Nmglu
cyclopentylalanine	Cpen	Chexa L-N-methylhistidine	Nmhis
15 D-alanine	Dal	L-N-methylisoleucine	Nmile
D-arginine	Darg	L-N-methylleucine	Nmleu
D-aspartic acid	Dasp	L-N-methyllysine	Nmlys
D-cysteine	Dcys	L-N-methylmethionine	Nmmet
D-glutamine	Dgln	L-N-methylnorleucine	Nmnle
20 D-glutamic acid	Dglu	L-N-methylnorvaline	Nmnva
D-histidine	Dhis	L-N-methylornithine	Nmorn
D-isoleucine	Dile	L-N-methylphenylalanine	Nmphe
D-leucine	Dleu	L-N-methylproline	Nmpro
D-lysine	Dlys	L-N-methylserine	Nmser
25 D-methionine	Dmet	L-N-methylthreonine	Nmthr
D-ornithine	Dorn	L-N-methyltryptophan	Nmtrp
D-phenylalanine	Dphe	L-N-methyltyrosine	Nmtyr
D-proline	Dpro	L-N-methylvaline	Nmval
D-serine	Dser	L-N-methylethylglycine	Nmetg
30 D-threonine	Dthr	L-N-methyl-t-butylglycine	Nmtbug
		L-norleucine	Nle

- 9 -

D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgabu
D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
5 D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap
D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
10 D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
15 D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
20 D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D- $\alpha$ -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
D- $\alpha$ -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpo
25 D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
30 D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser

- 10 -

D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
5 D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
10 D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyla-naphthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
$\gamma$ -aminobutyric acid	Gabu	N-( <i>p</i> -hydroxyphenyl)glycine	Nhtyr
L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
15 L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg
20 L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomophenylalanine	Mhphe
L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L- $\alpha$ -methylleucine	Mleu	L- $\alpha$ -methyllysine	Mlys
L- $\alpha$ -methylmethionine	Mmet	L- $\alpha$ -methylnorleucine	Mnle
25 L- $\alpha$ -methylnorvaline	Mnva	L- $\alpha$ -methylornithine	Morn
L- $\alpha$ -methylphenylalanine	Mphe	L- $\alpha$ -methylproline	Mpro
L- $\alpha$ -methylserine	Mser	L- $\alpha$ -methylthreonine	Mthr
L- $\alpha$ -methyltryptophan	Mtrp	L- $\alpha$ -methyltyrosine	Mtyr
L- $\alpha$ -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 11 -

N-(N-(2,2-diphenylethyl) carbamylmethyl)glycine Nnbhm  
1-carboxy-1-(2,2-diphenyl- ethylamino)cyclopropane Nmbc

N-(N-(3,3-diphenylpropyl) carbamylmethyl)glycine Nnbhe

5

---

The present invention further contemplates modified animals with altered expression levels of an Eph receptor or its functional equivalent. Such modified animals include "knock-out" murine animals such as "knock-out" mice. Alternatively, the modified animals have increased expression levels of the Eph receptor or its functional equivalent or expression in particular tissue or targeting expression in a region surrounding the CST.

The preferred Eph receptor is EphA4 or its functional equivalent in murine species or non-murine species (e.g. humans).

15

The present invention further extends to agonists and antagonists of an Eph receptor such as EphA4 or its functional equivalent and pharmaceutical compositions comprising same. The present invention also extends to genetic molecules encoding the Eph receptor or its functional equivalent or encoding an agonist, antagonist or ligand thereof. Particularly useful antagonists comprise monomeric Eph receptor molecules or their functional equivalents, soluble forms of the Eph receptor ligands (e.g. epherins) or molecules detected following screening of natural product or chemical libraries. Particularly useful epherins include ephrin B3 and EphA4-binding epherins.

25 The use of the expression of the Eph receptor to guide axonal movement has therapeutic implications including the use of Eph receptors to direct therapeutic molecules to particular targets.

The present invention is now further described with reference to the preferred Eph receptor, 30 EphA4 and to a "knock-out" mouse for the EphA4 gene. This is done, however, with the

- 12 -

understanding that the present invention extends to any Eph receptor or its functional equivalent which is involved in axonal guidance in humans or non-human animals. Reference to non-human animals include livestock animals (e.g. sheep, horses, pigs, donkeys, cows), laboratory test animals (e.g. mice, rats, guinea pigs, hamsters), companion animals (e.g. dogs, cats) and captured wild animals.

The EphA4 null (i.e. "knock-out") mutant mice are the first Eph receptor null mice to display a motor phenotype (7-9). This motor defect is more marked in the hindlimbs and the animals have an abnormal 'hopping' gait. Analysis of the CST in these animals reveal a reduced number of CST axons in the lower spinal cord segments and an abnormal pattern of termination at higher segments of the spinal cord and medulla. This progressive diminution of the CST, relative to normal animals, along the length of the cord is consistent with the more marked motor defect observed in the lower limbs of these animals. Additionally, it has been observed that some rats which have had their CST disrupted by transection also show a phenotype with a hopping gait similar to the EphA4 null mutants. Thus, a defective CST accounts for the motor defect.

The perturbation of the CST in null mutant animals establishes that EphA4 is required for CST development. During CST development, the first pioneering axons to advance down the spinal cord are those that will innervate the lumbar segments and these are then followed by a bulk of later arriving fasciculating CST fibres projecting to upper cord segments (18). As the primary growth cones of corticospinal axons continue to elongate down the midline of the spinal cord, the brainstem and spinal cord targets are contacted by collateral branches sprouted along the corticospinal axon shafts (32). The paucity of CST axons observed within the lumbar spinal cord regions in the EphA4 mutants are presumably due to misguidance of the primary cortical axons. It is possible that guidance of the collateral branches along the whole CST are also disrupted. Altogether, these data strongly indicate that EphA4 regulates axon guidance in the CST.

30 The immunohistochemistry and *in situ* hybridization data suggest that EphA4 is not expressed by cortical motor neurons or in the CST during its development. However, EphA4 was found

- 13 -

highly expressed within the intermediate and ventral regions of the spinal cord which is the region where the CST axons do not normally terminate. This is consistent with the notion that EphA4 is expressed on structures surrounding the CST where it acts as a signal for CST axons bearing Ephrin ligands to be appropriately guided. Also consistent with this model, EphrinB3  
5 mRNA was detected within the sensorimotor cortex at E18.5 which suggests that this transmembrane ligand is expressed on CST axons as they extend through the brain and spinal cord. EphA4 binds to EphrinB3 with high affinity and the transmembrane Ephrin ligands have been shown to induce signalling upon receptor binding (12, 13, 33, 34).

10 Both *in vitro* and *in vivo* studies have suggested that the Eph receptor family regulate axon guidance through mechanisms of contact repulsion rather than attraction (5, 6, 35, 36). For example, in EphB2 receptor-null mice the posterior tract of the AC innervates the floor of the brain aberrantly (7). EphB2 is normally expressed in areas ventral to the commissure and the commissural axons express a ligand for EphB2, Ephrin-B1. This suggests, therefore, that  
15 EphB2 repels AC axons from entering this ventral area via Ephrin-mediated signals (33, 34).

The present invention is consistent with a similar mechanism relating to guidance of the CST.

Another molecule found to be involved in CST development is the neural cell adhesion molecule, L1. In mice deficient in L1 many of the CST axons failed to decussate at the  
20 medulla, passing ipsilaterally into the dorsal columns (31). Similar to EphA4 null mice, the number of CST axons within the dorsal funiculus of the spinal cord was reduced and these axons did not project beyond the cervical levels. It was proposed that the interaction of L1 on the axons with CD24 (expressed in the midline) may modify the CST axons response to midline inhibitory cues, thereby allowing the axons to cross the midline. Another molecule  
25 shown to act as a guidance cue for CST axons is Netrin-1 (37). It was shown that the pathfinding of CST axons from the cortex to the internal capsule of the forebrain may be mediated by the chemoattractive activity of Netrin-1. Although not intending to limit the present invention to any one theory or mode of action, it is proposed herein that CST axons are guided by the combined actions of a number of attractive and repulsive guidance cues.

mammalian neural development. The inventors show that EphA4 may not be required for initial corticospinal tract development and that it is also not required for adult pinal motoneuron morphological development and survival. However, the inventors do show that EphA4 plays an important role in the correct topographic positioning of some spinal cord 5 motoneuron populations. EphA4 is expressed in specific areas of the brain during late embryonic development. These data provide an explanation for the axonal abnormalities observed in the EphA4 null mutant. The inventors show that EphA4 is widely expressed in the adult spinal cord after traumatic injury and this may contributed to the lack of axonal regeneration observed following spinal cord trauma. This knowledge of EphA4 expression 10 after injury is important for the clinical treatment of spinal cord injury as well as other central nervous system diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.

The present invention is further described by the following non-limiting Figures and 15 Examples.

In the Figures:

**Figure 1** is a representation showing targeted disruption of EphA4 gene. (A) Partial map of 20 the *ephA4* genomic locus (+/+) with the targeting construct and the resulting targeted loci (o/o). The EphA4 targeting vector was designed to replace exon III (217bp-880bp of EphA4 cDNA) (38) with the 1.8kb neomycin selection gene. For homologous recombination, 5' *Hind*III-*Sac*I 3kb sequence and 3' *Eco*47III-*Bam*HI 5.5kb sequence flanking exon III were subcloned into the pKJ1 vector. Homologous recombination would cause a frame shift in the EphA4 gene 25 resulting in a null mutant protein (Fig. 4.2). The probe used for all Southern analysis was a 1kb genomic fragment containing exon II (149bp-216bp) and *Eco*RI site. Ec, *Eco*RI; H, *Hind*III; S, *Sac*I; E47, *Eco*47III; B, *Bam*HI; Neo, neomycin gene; II, exon II; III, exon III. (B) Genotype analysis of EphA4 homozygous (o/o), heterozygous (+/o), and wild type (+/+) animals. Genomic DNA was isolated from 0.5cm tail tissue (39), digested with *Eco*RI and 30 subjected to Southern blot analysis using the 5' external probe shown in A. Alleles bearing the *ephA4* mutation results in a 5kb band, whereas an 11kb band is observed in the wild type

- 15 -

alleles. (C) Whole-mount immunocytochemistry of E8.5 embryos using anti-EphA4 antibody. EphA4 is expressed in rhombomeres 3 and 5 (arrows) in heterozygotes (+/o), but no EphA4 protein is detected in homozygous (o/o) mutants. The embryos were genotyped by PCR from yolk sac DNA.

5

**Figure 2** is a photographic representation of histological sections of EphA4 homozygous (o/o) and wild type (+/+) animals. (A) Transverse sections stained with luxol fast blue of lumbar spinal cord from adult mice. Area of the dorsal funiculus (df) appears to be shallower in EphA4 homozygotes. Scale bar = 160 $\mu$ m. (B) Coronal sections stained with haematoxylin and eosin of E16 embryo brains. A loss of the anterior commissure (ac) is observed in homozygotes. Scale bar = 140 $\mu$ m.

**Figure 3** shows labelled CST in normal (+/+ and +/o) and EphA4 null mutant (o/o) mice. (A). Schematic representation of the corticospinal projection traced in mice. Multiple injections of the tracer was made in the motor cortex in the left cerebral hemisphere of adult mice. The labelled CST axons descend through the midbrain, pons and pyramid in the medulla. In wild type and heterozygous mice, the CST axons decussate at the medulla, crossing the midline travelling from left ventral to right dorsal, enter the dorsal funiculus of the spinal cord and terminate predominantly in the dorsal horn contralateral to the tracer injections. In EphA4 null mutant mice, labelled CST axons appeared to terminate in the medulla and intermediate and ventral region of the spinal grey matter. Some labelled fibres were observed to recross the midline. PAG, periaqueductal grey; ICP, inferior cerebellar peduncle; V, trigeminal nucleus; IO, inferior olive; RN, red nucleus; NRM, nucleus raphe magnus; VII, facial nucleus; cun, cuneate nucleus. (B) Transverse sections of medulla showing the decussation of labelled CST fibres travelling from left ventral (v) to right dorsal (d). In EphA4 o/o mice, many CST axons do not enter the dorsal column area. Scale bar = 450 $\mu$ m. (C and D) Transverse sections of cervical spinal cord showing area of dorsal funiculus (C) and dorsal horn (D). In wild type animals, labelled CST axons terminate in the right dorsal horn (arrow). In homozygotes, axons project predominantly into the intermediate and ventral regions of the grey matter, and no labelled axons were observed terminating in the dorsal horn. cc, central canal; df, dorsal funiculus. Scale bar = 125 $\mu$ m. (E) Longitudinal sections of cervical spinal cord. CST axons

- 16 -

in the right dorsal funiculus are seen in the midline. In homozygous animals some CST fibres recross the midline and project to the grey matter ipsilateral to the tracer injections. Scale bar = 300 $\mu$ m. (F) Transverse sections of lumbar spinal cord. A reduced number of labelled CST axons was observed in the dorsal funiculus of the null mutant mice compared to normal. Scale bar = 125 $\mu$ m.

Figure 4 is a photographic representation showing analysis of EphA4 expression in wild type neonatal mouse tissues by immunohistochemistry (A) and in situ hybridization (B and C). (A) Coronal section of the medulla stained with anti-EphA4 antibody. EphA4 was detected in the inferior olivary nucleus (ol), but not in the pyramidal tract (py). Scale bar = 125 $\mu$ m. (B) Dark-field photomicrograph showing a coronal section of brain hybridized with radiolabelled-antisense EphA4 probe. The level of EphA4 mRNA within the sensorimotor cortex (sm) region is not above background. Scale bar = 420 $\mu$ m. (C) Dark-field, and (D) bright-field, photomicrograph of cervical spinal cord transverse section hybridized with antisense EphA4 probe. EphA4 mRNA is found expressed within the intermediate and ventral regions of the spinal cord grey matter. df, dorsal funiculus. Scale bar = 150 $\mu$ m. No signal was observed in equivalent tissue sections stained with radiolabelled-sense probe.

Figure 5 is a photographic representation showing analysis of EphrinB3 expression in wild type E18.5 mouse tissue by in situ hybridization. Coronal sections of whole head were hybridized with DIG-labelled (A) antisense Ephrin B3 and (B) sense riboprobes. An intense signal of Ephrin B3 mRNA is detected within the sensorimotor (sm) cortex region. Scale bar = 400 $\mu$ m.

Figures 6A to C are photographic representations defining the localisation of EphA4 expression in the brain and spinal cord of a 17.5 day old mouse wild type embryo.

Figures 7A and B are photographic representations defining the localisation of EphA4 protein in cross sections of the adult spinal cord after a trauma injury (A) and in an uninjured control (B).

- 17 -

## EXAMPLE 1

### MATERIALS AND METHODS

**Targeted disruption of EphA4 gene.** For homologous recombination, 5' *Hind*III-*Sac*I 3kb sequence and 3' *Eco*47III-*Bam*HI 5.5kb sequence flanking exon III were subcloned into the pKJ1 vector (Fig 1). The vector contains the neomycin-resistance gene (*neo*) with the phosphoglycerate kinase (*pgk*) promoter and *pgk* polyadenylation signal. The W9.5 embryonic stem cell line was electroporated with the *Sal*I linearized targeting construct and selected with G418 for 10 days. A total of 480 surviving clones were expanded and homologous recombinants were identified by Southern analysis of genomic DNA from single clones digested with *Eco*R1. Two isolated clones with a single targeted mutation of EphA4 gene were each injected into (C57BL/6 x C57BL/10)F<sub>2</sub> blastocysts. Chimeras were mated to C57BL/6 mice to produce heterozygotes. Southern analysis of tail DNA was used for genotyping the offspring.

15

#### **Whole-mount and Tissue Immunocytochemistry and PCR Genotyping of Embryos.**

Whole-mount immunocytochemistry was performed with anti-EphA4 antibody (available from D.G. Wilkinson of NIMR, Mill Hill, UK) as previously described (19) and colour detection was carried out using BCIP/NBT (Promega) as substrate. For tissue sections, tissues were fixed for 24 hours in 4% v/v paraformaldehyde and then another 24 hours in fixative containing 30% w/v sucrose. Frozen tissue was serially sectioned 50µm thick. Immunohistochemistry was performed using anti-EphA4 antibody and the same protocol as for whole mounts, except the ABC Elite detection system (Vector Laboratories, Burlingame CA) was used to detect colour staining.

25

Embryos were genotyped by PCR of yolk sac DNA (20) using primer pairs P1  
CGTGCTACTTCCATTGTCACGTCTG [SEQ ID NO:1] and P2  
TGCCGTGATAGCAAATTGAG [SEQ ID NO:2] or P3  
AGGAAGTGAGCATTATGGATGA [SEQ ID NO:3] and P4

30 TGCTCCTCGTGCCCAGCGTT [SEQ ID NO:4]. A 600bp band is generated from the mutant allele between the neomycin primer P1 and *ephA4* endogenous primer P2; a 645bp product is

- 18 -

generated from the wild type allele between exon III primers, P3 and P4. The PCR reaction was in a total volume of 50 $\mu$ l and consisted of 50-500ng DNA, 30pmoles of each primer, 2.0mM MgCl, 100 $\mu$ M dNTPs, 1 U Taq polymerase (Roche) with the appropriate reaction buffer supplied by the manufacturer. The cycling reaction was 15 cycles of 96 $^0$ C for 30 sec, 5 70 $^0$ C for 30 sec (-1 $^0$ C per cycle) and 72 $^0$ C for 1 min, followed by 20 cycles of 96 $^0$ C for 30 sec, 55 $^0$ C for 30 sec, and 72 $^0$ C for 1 min.

**Histology.** Histological examination was carried out on EphA4 homozygous, heterozygous and wild type littermates of embryonic age E16, 8 day and 24 day old mice. Embryos and 10 adult tissues were fixed overnight in 10% v/v formalin, paraffin-embedded and serially sectioned 4 $\mu$ m thick. Sections were stained with either haematoxylin and eosin or luxol fast blue.

**In-situ Hybridization.** For EphA4 mRNA expression, tissues were fixed overnight in 10% 15 formalin, paraffin-embedded and serially sectioned 4 $\mu$ m thick. In situ hybridization was performed as previously described (21) using  $^{33}$ P-radiolabeled complimentary EphA4 RNA probe. The antisense probe was synthesized with T7 polymerase from the *Hind*III-linearized plasmid Bluescript KS, containing a 1.5kb EcoRI fragment of 3' untranslated and C-terminal coding sequences of EphA4 (provided by D.G. Wilkinson of NIMR, Mill Hill, UK).

20

For expression of EphrinB3 mRNA, DIG-labelled in situ hybridization was performed on frozen 20 $\mu$ m tissue sections as previously described (22). To generate the Ephrin B3 probe, Ephrin B3 cDNA was amplified by PCR from adult mouse brain cDNA, using primers TTAGAATTCCCCGAGGGAGGAGCTGTAC [SEQ ID NO:5] and 25 CTAGAATTCTGCAGTCCCACCACCCCG [SEQ ID NO:6]. The PCR product, which spans 551bp to 953bp of Ephrin B3 cDNA (13), was cloned into EcoRI site of Bluescript SK and sequenced. The antisense probe was then synthesized with T3 polymerase from the *Hind*III-linearized plasmid.

30 **Surgery, Anterograde Tracing and Tissue Processing.** Corticospinal axons and their terminal projections were labelled in 5 week old mice using the anterograde tracer,

- 19 -

Biotinylated Dextran Amine (BDA, 15%) (Molecular Probes, Eugene, ON). Two wild type, one heterozygous, and three homozygous EphA4 mutant mice were used for these studies. The animals were anaesthetised by injecting intraperitoneal (10 $\mu$ l/gm body weight) a 1:1:6 ratio mixture of Hypnorm (Janssen, Oxford, UK), Hypernovel (Roche), and distilled H<sub>2</sub>O.

5 Anaesthetised animals had their head positioned in a stereotaxic frame and a craniotomy (3-4 mm in diameter) was made to expose the rostral half of the left cerebral hemisphere. Seven injections of 0.3  $\mu$ l of tracer were made into the cerebral cortex at a depth of 0.5 - 1.0 mm below its surface using a glass pipette (tip diameter 50  $\mu$ m) attached to a Hamilton syringe (23). The injections covered the whole sensorimotor region of the cerebral cortex. The  
10 number of injections, the injection sites and the amount of tracer used per injection were kept consistent between control and mutant animals. The brain and spinal cord were perfused 7 days following the injection with 0.9% w/v phosphate buffered saline and 4% v/v paraformaldehyde in phosphate buffer (PB). The tissue was postfixed for 24 hours in 30% w/v sucrose in buffered fixative.

15

The free-floating sections were processed according to the method as described (24) in order to visualise the axons and terminals labelled by BDA. Phosphate buffer (0.1M) was the vehicle for the immunoreagents and for rinsing after each of the following steps: (a) incubation in 0.3% v/v hydrogen peroxide in methanol for 20 mins to block any endogenous peroxidase  
20 activity (b) incubation in Avidin-peroxidase (Sigma) diluted 1:5,000 in 0.1M phosphate buffer and 0.75% v/v Triton X-100 for 2 hours (c) processing for horseradish peroxidase histochemistry using cobalt-enhanced diaminobenzidine (DAB) reaction (25) for 8-10 mins. This process stained the axons and terminals labelled with BDA black. Transverse spinal cord sections were counter-stained with haematoxylin.

25

## EXAMPLE 2

### GENERATION OF EPHA4 HOMOZYGOUS MICE

EphA4 deficient mice were generated using targeted mutagenesis and embryonic-stem (ES)  
30 cell technology (26). The gene targeting strategy (Fig 1A) replaces exon III with a neomycin selection gene thereby introducing a frame shift and stop codon in the *ephA4* gene. To

- 20 -

demonstrate that the EphA4 mutation results in a null mutation, whole-mount immunohistochemistry was performed on E8.5 embryos (Fig 1C). In wild type and heterozygous embryos, EphA4 was expressed in rhombomeres 3 and 5 (arrows), as previously described (14). In contrast, no staining was observed in the EphA4 homozygous embryos. The antibody recognises the C-terminus of the intracellular domain (2783-3195 residues) of EphA4 (19) and thus, the lack of staining observed in the homozygous embryos implies that no EphA4 protein is produced in these mutant mice. EphA4 null mutant mice generated from two independent ES cell lines were viable and fertile. The number of EphA4 homozygous mice in litters born from crossing heterozygotes showed a normal Mendelian ratio (25%), indicating no lethality of the mutation during embryogenesis.

### EXAMPLE 3

#### EPHA4 HOMOZYGOUS MICE DISPLAY AN ABNORMAL HOPPING GAIT

The EphA4 null mice exhibited locomotor abnormalities with impairment of the co-ordinated movement of the limbs. Both mouse strains showed hesitation in initiating locomotion, and once they began to move there was lack of the normal synchronous movement of each forelimb with the contralateral hindlimb. Most striking was an abnormal, synchronous, "kangaroo-like" movement of the hindlimbs while reciprocal movement of the forelimbs was maintained. In contrast, the heterozygous mice showed no abnormality.

Tests of neurological function were performed to further characterize the defects in these animals. The hesitation to move and lack of co-ordination in the hindlimbs was reflected in open field activity tests (27) which showed the distance travelled by the EphA4 homozygotes was only 30% of the heterozygote value (EphA4 homozygotes crossed  $18 \pm 24$  grids per 5 minutes compared to heterozygous littermates which crossed  $60 \pm 34$  grids, n= 15, p< 0.0005). In addition, the EphA4 null mutant animals showed placing deficits of both hindlimbs, suggesting a defect in corticospinal projections (28, 29), whereas sensory tests were within normal limits.

- 21 -

#### EXAMPLE 4

#### DISRUPTION OF SPINAL CORD ARCHITECTURE AND THE ANTERIOR COMMISSURE IN EPHA4 HOMOZYGOUS MICE

5 Anatomical studies were performed to determine if there were major structural changes in the central nervous system of the EphA4 null mice. While there was no macroscopic abnormality, histological analysis of spinal cord sections showed that the dorsal funiculus was markedly shallower in the EphA4 null animals compared to heterozygous and wild type animals (Fig 2A). The major motor pathway, the corticospinal tract (CST), descends through the dorsal 10 funiculus in the rodent spinal cord. Anatomical studies revealed a further defect in the EphA4 null mutant mice, a loss of the anterior commissure (AC). This was observed in 12 of the 14 homozygous specimens examined (Fig 2B), but appeared normal in all heterozygous and wild type mice. No other anatomical abnormalities were observed in the brains of EphA4 mutants, including within the motor cortex, midbrain, and medullary pyramids.

15

#### EXAMPLE 5

#### CORTICOSPINAL PROJECTION IS ABERRANT IN EPHA4 HOMOZYGOUS MICE

20 Functional tests and the abnormality in the dorsal funiculus suggested that the CST may be disrupted or absent in EphA4 deficient mice. This possibility was explored using dye tracing studies. Corticospinal axons were anterogradely labelled from their origin, layer V neurons in the motor cortex, to their terminal projections. Normally CST axons descend through the internal capsule, basis pedunculi in the midbrain, pons and medullary pyramids (Fig 3). In the 25 medulla the CST fibres cross the midline (decussate), then descend in the dorsal funiculus of the spinal cord and terminate predominantly in the dorsal horn contralateral to the cells of origin.

Anterograde labelling of corticospinal neurons in EphA4 null mice showed normal projection 30 within the fore- and mid-brain. However, the CST pathway within the medulla and spinal cord was clearly abnormal. It was observed in the medulla that, while many of the CST axons

- 22 -

crossed the midline, a considerable number of axons appeared to terminate inappropriately at this level, so that a reduced number of axons descended in the dorsal column of the spinal cord (Fig 3B). In addition, those axons which descended in the dorsal funiculus showed an aberrant pattern of termination within the grey matter of the spinal cord (Fig 3C and 3D), with terminal branches observed predominantly in the intermediate zone and ventral horn and very few terminals in the dorsal horn. A number of axons also recrossed the midline and terminated in the grey matter ipsilateral to the cortical tracer injection (Fig 3E). In the lumbar cord, there was a significant reduction in the number of CST axons (Fig 3F), making it difficult to demonstrate whether their pattern of termination was also aberrant at this level.

10

A small proportion of CST axons do not decussate in the medulla, but continue to descend ipsilaterally into the spinal cord in the ventral funiculus (30). The ipsilateral CST found within the ventral funiculus does not appear to be notably different in homozygous, heterozygous and wild type animals.

15

#### EXAMPLE 6

##### EXPRESSION OF EPHA4 AND LIGAND DURING CST DEVELOPMENT

To determine whether EphA4 protein was expressed in the CST, immunohistochemical studies 20 were undertaken on neonatal mouse brain tissues, which is the period when the CST projects through the medulla and enters the spinal cord (31, 32). EphA4 protein was not detected within the medullary pyramid or any other part of the CST at this age, however, it is expressed in the olfactory nucleus which is dorsal to the pyramidal tract (Fig 4A). In addition, *in situ* hybridization studies were undertaken to determine whether EphA4 mRNA was detected 25 within the motor cortex, which is where the cell bodies of the CST are localized. Consistent with the immunohistochemistry data, *in situ* hybridization analysis shows levels of EphA4 mRNA within the sensorimotor cortex which are not above background (Fig 4B). However, a gradient expression of EphA4 mRNA was found within the spinal cord with high levels of expression detected in the intermediate and ventral regions of the spinal cord grey matter and 30 low levels of expression in the dorsal horns (Fig. 4C). This data indicate that EphA4 is not expressed in the CST axons but is found expressed in surrounding structures.

- 23 -

To determine whether a ligand for EphA4 may be expressed in the CST, the inventors analysed the expression of Ephrin B3 within E18.5 mouse brain tissue (Fig 5). Of the transmembrane ligands, Ephrin B3 binds to EphA4 with the highest affinity (12, 13). *In situ* hybridization with the DIG-labelled Ephrin B3 antisense probe detected strong expression within the sensorimotor cortex region (Fig. 5A) thereby suggesting that Ephrin B3 is expressed in the motor neurons of the CST during its development.

#### EXAMPLE 7

**EphA4 DOES NOT PLAY A SIGNIFICANT ROLE IN THE EARLY EMBRYONIC  
10 DEVELOPMENT OF THE CST**

In this experiment, corticofugal axons are labelled with Dil in coronal sections of W/W and O/O E14 brains. Corticofugal axons in the O/O exhibited no obvious growth abnormalities at this stage and the number of processes reaching the internal capsule (IC) is not reduced, 15 indicating that disruption of EphA4 does not greatly affect initial process guidance or neuronal viability.

#### EXAMPLE 8

**EphA4 DOES NOT SIGNIFICANTLY AFFECT LUMBAR SPINAL  
20 CORD MOTONEURON SURVIVAL**

Lumbar spinal motoneurons were retrogradely labelled in the W/W and O/O using the fluorescent tracers Tetramethylrhodamine and Fast Blue. Motoneurons of the O/O exhibited no obvious morphological differences when compared to the W/W. Furthermore, when the 25 numbers of retrogradely labelled motoneurons that innervate the sciatic nerve are stereologically counted. Results indicated that there is no significant difference between the numbers of motoneurons in the W/W and O/O indicating that EphA4 may not be required for survival of some populations of lumbar spinal motoneurons.

**EXAMPLE 9****EphA4 MAY BE REQUIRED FOR THE CORRECT TOPOGRAPHIC POSITIONING OF SOME LUMBAR SPINAL CORD MOTONEURON POPULATIONS**

5

Labelling discrete lumbar spinal motoneuron populations with various fluorescent tracers revealed that in the O/O, the population of motoneurons that innervate the tibialis anterior muscle appear to have migrated further caudally than those observed in the W/W. In contrast, the motoneuron populations innervating the gastrocnemius muscle and sciatic nerve in the O/O 10 appear to be topographically similar to the homologous populations labelled in the W/W.

**EXAMPLE 10****EphA4 IS EXPRESSED IN SPECIFIC AREAS DURING BRAIN DEVELOPMENT**

15 Shown in Figures 6A-C are photographic representations defining the localisation of EphA4 expression in the brain and spinal cord of a 17.5 day old mouse wild type embryo. Left panel: localisation of EphA4 receptor protein by immunohistochemistry using an EphA4 specific antibody and fluorescence staining. Right panel: localisation of EphA4 messenger RNA (mRNA) by *in situ* hybridisation using a radiolabeled EphA4 specific antisense probe (positive 20 labelling appears as clusters of white dots).

A. Cross section through the brain in the region of the hippocampus (Hip). EphA4 expression is found in the hippocampus, sensorimotor cortex (Sm) and the caudate putamen (Cp).

25 B. Cross section through the medullary region of the brain. EphA4 protein expression was not detected within the medullary pyramid (Py) or any other part of the CST during any stage of development, but both EphA4 mRNA and protein was found to be strongly expression in the olfactory region (OR), which is directly dorsal to the pyramidal tract.

30 C. Cross section through the cervical spinal cord. EphA4 protein and mRNA is found in the intermediate and ventral regions of the spinal cord grey matter but not in the dorsal horns.

- 25 -

These data indicate that EphA4 is not expression on the CST axons but is expression in the surrounding environment through which they grow.

#### EXAMPLE 11

##### 5      **EphA4 PROTEIN IS EXPRESSED FOLLOWING SPINAL CORD TRAUMA**

Shown in Figures 7A and B are photographic representations defining the localisation of EphA4 protein in cross sections of the adult spinal cord after a trauma injury (A) and in an uninjured control (B). Strong EphA4 expression is found in the injured spinal cord 10 predominantly in the white matter (WM). The white matter surrounds the dorsal and ventral horns (DH and VH) of the spinal cord and is the area where axon tracts ascend and descend. Note that expression is found in dorsal funiculus (arrowhead) which is where the CST descends the spinal cord. No EphA4 expression is found in the uninjured spinal cord.

15 These data indicate that large areas of EphA4 expression after injury may inhibit regeneration of new axons in the adult spinal cord.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood 20 that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

- 26 -

## BIBLIOGRAPHY

1. Brambilla, R. & Klein, R. (1995) *Mol.Cell.Neurosci* **6**, 487-495.
2. Tessier-Lavigne, M. (1995) *Cell* **82**, 345-348.
3. Friedman, G.C. & O'Leary, D.D.M. (1996) *Curr.Opin.Neurobiol* **6**, 127-133.
4. Cheng, H.J., Nakamoto, M., Bergemann, A.D. & Flanagan, J.G. (1995) *Cell* **82**, 371-381.
5. Drescher, U., Kremoser, C., Handwerker, C., Loschinger, J., Noda, M. & Bonhoeffer, F. (1995) *Cell* **82**, 359-370.
6. Nakamoto, M., Cheng, H.J., Friedman, G.C., McLaughlin, T., Hansen, M.J., Yoon, C.H., O'Leary, D.D.M. & Flanagan, J.G. (1996) *Cell* **86**, 755-766.
7. Henkemeyer, M., Orioli, D., Henderson, J.T., Saxton, T.M., Roder, J., Pawson, T. & Klein, R. (1996) *Cell* **86**, 35-46.
8. Orioli, D., Henkemeyer, M., Lemke, G., Klein, R. & Pawson, T. (1996) *EMBO J* **15**, 6035-6049.
9. Park, S., Frisen, J. & Barbacid, M. (1997) *EMBO J* **16**, 3106-3114.
10. Orioli, D. & Klein, R. (1997) *TIG* **13**, 354-359.
11. Gale, N.W., Holland, S.J., Valenzuela, D.M., Flenniken, A., Pan, L., Ryan, T.E., Henkemeyer, M., Strebhard, K., Hirai, H., Wilkinson, D.G., Pawson, T., Davis, S. & Yancopoulos, G.D. (1996) *Neuron* **17**, 9-19.
12. Gale, N.W., Flenniken, A., Compton, D.C., Jenkins, N., Copeland, N.G., Gilbert, D.J., Davis, S., Wilkinson, D.G. & Yancopoulos, G.D. (1996) *Oncogene* **13**, 1343-1352.
13. Bergemann, A.D., Zhang, L., Chiang, M., Brambilla, R., Klein, R. & Flanagan, J.G. (1998) *Oncogene* **16**, 471-480.
14. Nieto, M.A., Gilardi-Hebenstreit, P., Charnay, P. & Wilkinson, D.G. (1992) *Development* **116**, 1137-1150.
15. Mori, T., Wanaka, A., Taguchi, A., Matsumoto, K. & Tohyama, M. (1995) *Brain Res. Mol. Brain Res.* **29**, 325-335.
16. Xu, Q., Alldus, G., Holder, N. & Wilkinson, D.G. (1995) *Development* **121**, 4005-4016.

- 27 -

17. Xu, Q., Alldus, G., Macdonald, R., Wilkinson, D.G. & Holder, N. (1996) *Nature* **381**, 319-322.
18. Stanfield, B.B. (1992) *Prog. Neurobiol.* **38**, 169-202.
19. Irving, C., Nieto, M.A., DasGupta, R., Charnay, P. & Wilkinson, D.G. (1996) *Dev. Biol.* **173**, 26-38.
20. Robb, L., Lyons, I., Ruili, L., Hartley, L., Kontgen, F., Harvey, R.P., Metcalf, D. & Begley, C.G. (1995) *Proc Natl Acad Sci USA* **92**, 7075-7079.
21. Lyons, I., Parsons, L.M., Hartley, L., Li, R., Andrews, J.E., Robb, L. & Harvey, R.P. (1995) *Genes & Dev.* **9**, 1654-1666.
22. Schaeren-Wiemers, N. & Gerfin-Moser, A. (1993) *Histochemistry* **100**, 431-440.
23. Galea, M. & Darian-Smith, I. (1997) *J. Comp. Neurol.* **381**, 282-306.
24. Rees, S., Rawson, J., Nitsos, I. & Brumley, C. (1994) *Brain Res.* **642**, 185-198.
25. Adams, J. (1981) *J. Histochem. Cytochem.* **29**, 775.
26. Capecchi, M.R. (1989) *Science* **244**, 1288-1292.
27. DeFries, J., Gervais, M. & Thomas, E. (1978) *Behavioural Genetics* **8**, 3-13.
28. Bregman, B.S. & Goldberger, M.E. (1982) *Science* **217**, 553-555.
29. Bregman, B.S., Kunkel-Bagden, E., Schnell, L., Dai, H.N., Gao, D. & Schwab, M.E. (1995) *Nature* **378**, 498-501.
30. Casale, E.J., Light, A.R. & Rustioni, A. (1988) *J Comp Neurology* **278**, 275-286.
31. Cohen, N.R., Taylor, J.S.H., Scott, L.B., Guillory, P., Soriano, P. & Furley, A.J.W. (1997) *Curr. Biol.* **8**, 26-33.
32. Bastmeyer, M. & O'Leary, D.D.M. (1996) *J Neurosci* **16**, 1450-1459.
33. Holland, S.J., Gale, N.W., Mbamalu, G., Yancopoulos, G.D., Henkemeyer, M. & Pawson, T. (1996) *Nature* **383**, 722-725.
34. Brückner, K., Pasquale, E.B. & Klein, R. (1997) *Science* **275**, 1640-1643.
35. Ohta, K., Iwamasa, H., Drescher, U., Terasaki, H. & Tanaka, H. (1997) *Mech. Dev.* **64**, 127-135.
36. Wang, H.u. & Anderson, D.J. (1997) *Neuron* **18**, 383-396.
37. Richards, L.J., Koester, S.E., Tuttle, R. & O'Leary, D.D.M. (1997) *J. Neurosci* **17**, 2445-2458.
38. Gilardi-Hebenstreit, P., Nieto, M.A., Frain, M., Mattei, M.G., Chestier, A., Wilkinson,

- 28 -

D.G. & Charnay, P. (1993) *Oncogene* **8**, 1103.

39. Laird, P.W., Ziderveld, A., Linders, K., Rudnicki, M.A., Jaenisch, R. & Berns, A. (1991) *Nucleic Acids Res.* **19**, 4293.

40. Lackmann, M. *et al.* (1998) *J. Biol. Chem.* **273**, 20228.

41. Howlett, K. *et al.* (1997) *J. Biol. Chem.* **272**, 16521.

## CLAIMS

1. A method of facilitating regeneration, growth and/or development of a central nervous system in an animal or bird said method comprising increasing elevating or otherwise enhancing the levels of a Eph receptor or its functional equivalent or a ligand thereof.
2. A method of regulating axon guidance in an animal or bird said method comprising increasing, elevating or otherwise enhancing the levels of an Eph receptor or its functional equivalent or a ligand thereof.
3. A method for facilitating the repair or replacement of axons or otherwise facilitating repair of nervous tissue in animal or bird, said method comprising increasing, elevating or otherwise enhancing the levels of an Eph receptors or its functional equivalent in a region surrounding the cortex and/or inhibiting, reducing or otherwise down-regulating expression of the Eph receptor or its functional equivalent when expressed in tissues outside said region surrounding the cortex and which expression leads to blockage of axonal growth.
4. A method according to any one of claims 1 to 3 wherein the animal is a mammal.
5. A method according to claim 4 wherein the mammal is a human.
6. A method according to any one of claims 1 or 3 in response to disease or trauma.
7. A method according to claim 6 wherein the disease or trauma is brain or spinal cord injury or disease of the upper motor neuron.
8. A method according to claim 1 or 2 wherein the Eph ligand is an ephrin or a functional equivalent thereof.

9. A method according to any one of claims 1 to 3 comprising administering soluble or near soluble forms of Eph receptors or their ligands or their functional equivalents or multimeric forms thereof.
10. A method according to claim 9 wherein Eph receptor or ligand administration is *via* the spinal cord or brain.
11. A method according to claim 10 wherein Eph receptor or ligand administration is facilitated by co-administration with the TAT gene of HIV.
12. A method according to claim 11 wherein Eph receptor or ligand administration is *via* intraperitoneal, intravenous or subcutaneous administration.
13. A method according to any one of claims 1 to 3 wherein the Eph receptor is EphA4.
14. A genetically modified animal producing reduced levels of an Eph receptor or ligand thereof or their functional equivalents.
15. A genetically modified animal producing elevated levels of an Eph receptor or ligand thereof or their functional equivalents.
16. A genetically modified animal according to claim 14 or 15 wherein the Eph receptor is EphA4 or its functional equivalent.
17. A genetically modified animal according to claim 14 or 15 or 16 wherein the animal is a murine species.
18. A composition useful in facilitating regeneration, growth and/or development of a control nervous system or regulating axon guidance or facilitating repair or replacement of axons or repair of nervous tissue said composition comprising an Eph receptor or ligand or

a functional equivalent thereof and one or more pharmaceutically acceptable carriers and/or diluents.

19. A composition according to claim 18 wherein the Eph receptor is EphA4.
20. A composition according to claim 18 wherein the ligand is an ephrin.
21. Use of an Eph receptor or its ligand or their functional equivalently in the manufacture of a medicament for the regeneration, growth and/or development of a central nervous system or for regulating axon guidance or for facilitating repair or replacement of axons or for facilitating repair of nervous tissue.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number:	WO 00/24413
A61K 38/16, 38/00		(43) International Publication Date:	4 May 2000 (04.05.00)
(21) International Application Number:	PCT/AU99/00931		
(22) International Filing Date:	27 October 1999 (27.10.99)		
(30) Priority Data:	<p>PP 6748 27 October 1998 (27.10.98) AU</p> <p>(71) Applicants (for all designated States except US): THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; Royal Parade, Parkville, Victoria 3052 (AU). THE COUNCIL FOR THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 300 Herston Road, Herston, Queensland 4006 (AU). THE UNIVERSITY OF MELBOURNE [AU/AU]; Grattan Street, Parkville, Victoria 3052 (AU).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BARTLETT, Perry, F. [AU/AU]; Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052 (AU). HARTLEY, Lynne [AU/AU]; Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052 (AU). PILIZZOTTO, Mark [AU/AU]; Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052 (AU). KILPATRICK, Trevor [AU/AU]; Walter and Eliza Hall Institute of Medical Research, Royal Parade,</p>		
	<p>Parkville, Victoria 3052 (AU). KONTGEN, Frank [DE/AU]; 5 Timberglades, Park Orchards, Victoria 3114 (AU). COONAN, Jason [AU/AU]; Unit 10, 831 Park Street, Brunswick, Victoria 3056 (AU). REFERATH, Ursula [DE/AU]; 366 Cardigan Street, Carlton, Victoria 3053 (AU). BOYD, Andrew, W. [AU/AU]; Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006 (AU). DOTTORI, Mirella [AU/AU]; Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006 (AU). GALEA, Mary [AU/AU]; University of Melbourne, Grattan Street, Parkville, Victoria 3052 (AU). TAXINOS, George [AU/AU]; The University of Melbourne, Grattan Street, Parkville, Victoria 3052 (AU). MURPHY, Mark [AU/AU]; The University of Melbourne, Grattan Street, Parkville, Victoria 3052 (AU).</p> <p>(74) Agents: HUGHES, E., John, L.; Davies Collison Cave, 303 Coronation Drive, Milton, Queensland 4064 (AU) et al.</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>		
(54) Title:	A METHOD OF TREATMENT		
(57) Abstract	<p>The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.</p>		
Published	<p>With international search report.</p>		

(54) Title: A METHOD OF TREATMENT




(57) Abstract

The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**A****B****C**


**Figure 1**  
Substitute Sheet (Rule 26) RO/AU

09/830319

WO 00/24413


2/8

PCT/AU99/00931



3/8

## Corticospinal projections in the mouse



### Legend:

PAG - periaqueductal grey  
 ICP - inferior cerebellar peduncle  
 V - trigeminal nucleus  
 IO - inferior olive


RN - red nucleus  
 NRM - nucleus raphe magnus  
 VII - facial nucleus  
 cun - cuneate nucleus

09/830319

WO 00/24413

PCT/AU99/00931

4/8



Substitute Sheet (Rule 26) RO/AU  
Figure 3 b,c,d,e,f




Figure 4

09/830319

WO 00/24413

PCT/AU99/00931

6/8





Figure 5

09/830319

WO 00/24413

PCT/AU99/00931

7/8



Substitute Sheet (Rule 36) RO/AU  
Figure 6

09/830319

WO 00/24413

PCT/AU99/00931

8/8




Figure 7

11- 9-01:16:12 :DAVIES COLLISON CAVE Pat. & Trad

11/08 '01 14:07 161 45 2508 CORY/WEHI

17- 7-01:14:19 :DAVIES COLLISON CAVE Pat. & Trad

161 7 3368 2262

003/010

# 15/ 2

37921/151292

**PATENT**  
**Attorney Docket No. 37921-151292**

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name:

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

**"A METHOD OF TREATMENT"**

the specification of which is attached hereto unless the following box is checked

was filed on October 27, 1999 as Application No. \_\_\_\_\_ or  
PCT Application No. PCT/AU99/00931 and amended on \_\_\_\_\_  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

37921/151292

**PRIOR FOREIGN/PCT APPLICATION(S)**

<b>COUNTRY/OFFICE</b>	<b>APPLICATION NO.</b>	<b>DATE OF FILING</b>	<b>PRIORITY CLAIMED</b>
AU	PP 6748	October 27, 1998	<input checked="" type="checkbox"/> YES NO <input type="checkbox"/>
			<input type="checkbox"/> YES NO <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

<b>PROVISIONAL APPLICATION NUMBER</b>	<b>DATE OF FILING</b>
---------------------------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120**

Status (check one)

<b>Application Serial No.</b>	<b>Date of Filing</b>	<b>Patented</b>	<b>Pending</b>	<b>Abandoned</b>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

And I hereby appoint Arthur H. Seidel, Registration No. 15,979; Gregory J. Lavorgna, Registration No. 30,469; Daniel A. Monaco, Registration No. 30,480; Thomas J. Durling, Registration No. 31,349; and John J. Marshall, Registration No. 29,671, my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

5  
Address all correspondence to Drinker Biddle & Reath LLP, One Logan Square, 18<sup>th</sup> & Cherry Streets, Philadelphia, PA 19103-6996. Address all telephone calls to Daniel A. Monaco, (215) 988-3312 (telefax: (215) 988-2757).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001

11- 9-01:16:12 ;DAVIES COLLISON CAVE Pat. & Trad

11/09 '01 14:08 261 345 2508 CORY/WEHI  
17- 7-01:14:19 ;DAVIES COLLISON CAVE Pat. & Trad

13 3388 2282 005/010  
# 17/2

37921/151292

of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**FULL NAME OF SOLE OR FIRST INVENTOR**

PERRY

(GIVEN NAME)

E.


(MIDDLE INITIAL OR NAME)

BARTLETT

(FAMILY OR LAST NAME)

100

Inventor's signature:



Date: 18/7/2001

Country of Citizenship: Australia

Residence: Victoria

Australia

Aux

(City)

Post Office Address:

(State or Foreign Country)

c/o Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052 Australia

**FULL NAME OF SOLE OR SECOND INVENTOR**

LYNNE


(GIVEN NAME)

HARTLEY

(FAMILY OR LAST NAME)

200

Inventor's signature:



Date: 19.07.01

Country of Citizenship: Australia

Residence: Victoria

Australia

Aux

(City)

Post Office Address:

(State or Foreign Country)

c/o Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052 Australia

11- 9-01;16:12 :DAVIES COLLISON CAVE Pat. & Trad  
11/09 '01 14:09 61 45 2508 CORY/WEHI  
17- 7-01:14:19 :DAVIES COLLISON CAVE Pat. & Trad

161 7 3568 2262 006/010 # 18/

37921/151292

FULL NAME OF SOLE OR THIRD INVENTOR

MARK

*Hoo*

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

Pozzotto MP-  
Pozzotto

(FAMILY OR LAST NAME)

Inventor's signature: *M. Pozzotto*

Date: *23/7/1*

Country of Citizenship: Australia

Residence: Victoria

Australia

*X*

(City)

Post Office Address:

(State or Foreign Country)

c/o Walter and Eliza Hall Institute of Medical  
Research, Royal Parade, Parkville, Victoria 3052 Australia

FULL NAME OF SOLE OR FOURTH INVENTOR

TREVOR

*Hoo*

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

KILPATRICK

(FAMILY OR LAST NAME)

*D. Kilpatrick*

Date: *18th July 2001*

Country of Citizenship: Australia

Residence: Victoria

Australia

*X*

(City)

Post Office Address:

(State or Foreign Country)

c/o Walter and Eliza Hall Institute of Medical  
Research, Royal Parade, Parkville, Victoria 3052 Australia

11- 9-01:16:12 :DAVIES COLLISON CAVE Pat. & Trad  
11/08 '01 14:09 861 45 2508 CORY/WEHI  
17- 7-01:14:19 :DAVIES COLLISON CAVE Pat. & Trad

37921/151292  
007/010

37921/151292

FULL NAME OF SOLE OR FIFTH INVENTOR

FRANK

(GIVEN NAME)

KONTGEN

(FAMILY OR LAST NAME)

500

(MIDDLE INITIAL OR NAME)



Inventor's signature:

Date: 26-07-01 25-07-01

Country of Citizenship: Germany

Residence: Victoria Western Australia Australia AU

(City)

(State or Foreign Country)

Post Office Address: 5 Timberglades, Park Orchards Victoria 3114 Australia 141 West Coast Drive North Beach WA 6020 FK Australia

FULL NAME OF SOLE OR SIXTH INVENTOR

JASON

(GIVEN NAME)

COONAN

(FAMILY OR LAST NAME)

Inventor's signature:

Date: 18-07-01

Country of Citizenship: Australia

Residence: Victoria Australia AU

(City)

(State or Foreign Country)

Post Office Address: Unit 10, 831 Park Street, Brunswick Victoria 3056, Australia

11- 9-01;16:12 ;DAVIES COLLISON CAVE Pat. & Trad  
11/09 '01 14:09 261 3 5 2508 CORY/WEHI  
17- 7-01;14:19 ;DAVIES COLLISON CAVE Pat. & Trad

11- 9-01;16:12 3 5 6 9 2 2 6 2 3 1 1 1 1 1 1 1  
11/09 '01 14:09 261 7 3 3 8 8 2 2 6 2 # 20/ 21  
37921/151292

FULL NAME OF SOLE OR SEVENTH INVENTOR

7-00

URSULA  
(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

GREFERATH  
(FAMILY OR LAST NAME)

Inventor's signature: M. GrefeRath

Date: 8 September 2007

Country of Citizenship: Germany

Residence: Victoria Australia Aux  
(City) Australia

Post Office Address: 366 Cardigan Street  
Victoria 3053, Australia

FULL NAME OF SOLE OR EIGHTH INVENTOR

8-00

ANDREW  
(GIVEN NAME)

W.  
(MIDDLE INITIAL OR NAME)

BOYD  
(FAMILY OR LAST NAME)

Inventor's signature: W. Andrew Boyd

Date: 27/7/2001

Country of Citizenship: Australia

Residence: Queensland Australia Aux  
(City) Australia

Post Office Address: c/o Queensland Institute Of Medical Research  
300 Herston Road, Herston  
Queensland 4006, Australia

11- 9-01:16:12 :DAVIES COLLISON CAVE Pat. & Trad  
11/08 '01 14:10 281 45 2508 CORY/WEHI  
17- 7-01:14:19 :DAVIES COLLISON CAVE Pat. & Trad

38 64 2262 39 1  
009/010 # 21/25  
81 7 3389 2262 # 21/25

37921/151292

FULL NAME OF SOLE OR NINETH INVENTOR

9-00

MIRELLA  
(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

DOTTORI  
(FAMILY OR LAST NAME)

Inventor's signature: Mirella Dottori  
Date: 28-8-01

Country of Citizenship: Australia

Residence: Queensland Australia Aux  
(City) (State or Foreign Country)  
Post Office Address: c/o Queensland Institute of Medical Research  
300 Herston Road  
Queensland 4006, Australia

FULL NAME OF SOLE OR TENTH INVENTOR

10-00

MARY  
(GIVEN NAME)

P.  
(MIDDLE INITIAL OR NAME)

GALEA  
(FAMILY OR LAST NAME)

Inventor's signature: Mary P. Galea  
Date: 6/9/01

Country of Citizenship: Australia

Residence: Victoria Australia Aux  
(City) (State or Foreign Country)  
Post Office Address: c/o The University of Melbourne  
Grattan Street, Parkville  
Victoria 3052, Australia

11- 9-01 16:12 :DAVIES COLLISON CAVE Pat. & Trad  
11/08 '01 14:10 261 345 2508 CORY/WEHI  
17- /-01 14:18 :DAVIES COLLISON CAVE Pat. & Trad

010/010

37921/151292

FULL NAME OF SOLE OR ELEVENTH INVENTOR

1100

GEORGE

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

PAXINOS

(FAMILY OR LAST NAME)

Inventor's signature:

George T. Paxinos

Date:

20/8/01

Country of Citizenship: Australia

Residence: Victoria

Australia

AU

(City)

Post Office Address:

(State or Foreign Country)

c/o The University of Melbourne  
Grattan Street, Parkville  
Victoria 3052, Australia

FULL NAME OF SOLE OR TWELFTH INVENTOR

1200

MARK

(GIVEN NAME)

MURPHY

(FAMILY OR LAST NAME)

Inventor's signature:

Mark Murphy

Date:

7/9/81

Country of Citizenship: Australia

Residence: Victoria

Australia

AU

(City)

Post Office Address:

(State or Foreign Country)

c/o The University of Melbourne  
Grattan Street, Parkville  
Victoria 3052, Australia

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: (other than US) THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, COUNCIL FOR THE QUEENSLAND INSTITUTE FOR MEDICAL RESEARCH LIMITED, UNIVERSITY OF MELBOURNE  
(US only) Perry F BARTLETT, Andrew W BOYD, Mirella DOTTORI, Lynne HARTLEY, Mary GALEA, George PAXINOS, Mark POLIZZOTTO, Trevor KILPATRICK, Mark MURPHY, Frank KONTGEN, Jason COONAN, Ursula GREFERATH

(ii) TITLE OF INVENTION: A METHOD OF TREATMENT

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: DAVIES COLLISON CAVE
- (B) STREET: 1 LITTLE COLLINS STREET
- (C) CITY: MELBOURNE
- (D) STATE: VICTORIA
- (E) COUNTRY: AUSTRALIA
- (F) ZIP: 3000

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: INTERNATIONAL (PCT)
- (B) FILING DATE: 27-OCT-1999
- (C) CLASSIFICATION:

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: AUSTRALIAN PROVISIONAL
- (B) FILING DATE: 27-OCT-1998
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: HUGHES, DR E JOHN L
- (C) REFERENCE/DOCKET NUMBER: EJH/AF

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +61 3 9254 2777
- (B) TELEFAX: +61 3 9254 2770
- (C) TELEX: AA 31787

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGTGCTACTT CCATTTGTCA CGTCCTG

27

## (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGCCGTGATA GCAAATTTGA G

21

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGGAAGTGAG CATTATGGAT GA

22

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGCTCCTCGT GCCCAGCGTT

20

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTAGAATTCC CCGAGGAGGA GCTGTAC

27

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear


(ii) MOLECULE TYPE: Oligonucleotides

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTAGAATTCT GCAGTCCCAC CACCCCG

27

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not  
present  
for scanning. (Document title)

*Scanned copy is best available. Some drawings are dark*